These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 29293382)

  • 1. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S; Habeeb SKM
    J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
    Pery N; Rizvi NB; Shafiq MI
    J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor.
    Lee KW; Lee WH; Han BS; Lee JH; Doo EK; Kim JH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357562
    [No Abstract]   [Full Text] [Related]  

  • 6. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors.
    Wang J; Ran T; Chen Y; Lu T
    Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
    J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
    Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT
    J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
    Joseph RE; Amatya N; Fulton DB; Engen JR; Wales TE; Andreotti A
    Elife; 2020 Nov; 9():. PubMed ID: 33226337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation.
    Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R
    Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
    Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
    J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B
    Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Fast and Clean BTK Inhibitor.
    Gabizon R; London N
    J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion of carbazole carboxamide based reversible inhibitors of Bruton's tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series.
    Liu Q; Batt DG; Chaudhry C; Lippy JS; Pattoli MA; Surti N; Xu S; Carter PH; Burke JR; Tino JA
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3080-3084. PubMed ID: 30097367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
    Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.